Meta-Analysisvery high evidence
Clopidogrel versus aspirin for secondary prevention of coronary artery disease: a systematic review and individual patient data meta-analysis.
Lancet (London, England)·September 13, 2025·PMID 40902613
Why it mattersCurrent guidelines recommend aspirin monotherapy indefinitely for secondary prevention in coronary artery disease. This large, high-quality meta-analysis provides robust evidence that clopidogrel may be superior, potentially influencing long-term antiplatelet choice in patients with established CAD, particularly those with prior PCI or ACS.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled